Report Description Table of Contents Biomarker-Guided Testing and Precision Oncology Reshape the Gastric Cancer Diagnostics Landscape – (Updated On: 14-Sep-2026) The Global Gastric Cancer Diagnostics Market was valued at USD 1.33 billion in 2025 and is projected to reach USD 2.17 billion by 2032, expanding at a CAGR of 7.35% during 2026–2032, according to Strategic Market Research. The Gastric Cancer Diagnostics Market refers to technologies and services used for detecting, confirming, staging, and molecularly characterizing gastric malignancies. The diagnostic pathway is primarily based on upper gastrointestinal endoscopy with biopsy confirmation, followed by imaging and biomarker testing to determine disease stage and guide treatment decisions. These solutions are used across hospitals, cancer centers, diagnostic laboratories, and academic institutions managing patients with suspected or confirmed gastric cancer. Gastric cancer remains a significant global oncology burden, with approximately 969,000 new cases and nearly 660,000 deaths annually worldwide, according to IARC estimates. In the United States, approximately 31,510 new stomach cancer cases are expected annually, including around 17,900 cases in men and 13,610 in women, with nearly 10,740 deaths each year. As treatment increasingly shifts toward targeted and immune-based therapies, accurate biomarker identification has become essential for optimizing patient outcomes. Roche’s VENTANA CLDN18 (43-14A) RxDx Assay identifies patients whose tumors have the CLDN18.2 marker, helping select those who may benefit from zolbetuximab (Vyloy). Agilent’s PD-L1 tests (28-8 and 22C3) measure PD-L1 levels to guide the use of immunotherapies such as nivolumab (Opdivo) and pembrolizumab (Keytruda). Roche’s HER2 testing solutions detect HER2-positive tumors, supporting treatment decisions for HER2-targeted therapies such as zanidatamab (Ziihera). Overall, the gastric cancer diagnostics market is evolving from conventional detection toward biomarker-driven, personalized diagnostic ecosystems, where advanced molecular testing plays a critical role in improving treatment precision, patient stratification, and therapeutic success. Product Mix, Diagnostic Technologies, Disease Types, and Care Settings Define Market Structure By Product Type Reagents & Consumables: Largest product segment with 50.0% share and USD 665 million in 2025, supported by recurring utilization of biopsy processing materials, molecular assay kits, and pathology reagents. Diagnostic Instruments: Represented 25.0% share with USD 333 million in 2025, driven by adoption of endoscopy systems, pathology analyzers, imaging equipment, and automated laboratory platforms. Diagnostic Systems & Platforms: Accounted for 25.0% share with USD 333 million in 2025 and recorded the fastest growth due to integrated molecular diagnostics and AI-enabled pathology adoption. By Diagnostic Technology Endoscopy & Biopsy: Leading technology segment with 35.0% share and USD 466 million in 2025, supported by its role as the definitive method for gastric cancer confirmation. Molecular Diagnostics: Held 20.0% share with USD 266 million in 2025, expanding through HER2, PD-L1, MSI, EBV, and genomic profiling applications. Immunohistochemistry (IHC): Represented 15.0% share with USD 200 million in 2025, supported by biomarker evaluation required for targeted and immune-based treatment selection. Imaging-Based Diagnostics: Accounted for 15.0% share with USD 200 million in 2025, driven by CT, PET-CT, MRI, and staging applications. Blood-Based Biomarker Testing: Held 15.0% share with USD 200 million in 2025, supported by emerging liquid biopsy and circulating tumor biomarker technologies. By Disease Type Gastric Adenocarcinoma: Dominated with 88.0% share and USD 1.17 billion in 2025 due to its status as the predominant gastric cancer subtype requiring extensive diagnostic evaluation. Gastric Lymphoma: Accounted for 8.0% share with USD 106 million in 2025, supported by diagnostic requirements for lymphoma classification and molecular assessment. Other Gastric Malignancies: Represented 4.0% share with USD 53 million in 2025, supported by improved recognition and characterization of rare gastric tumors. By End User Hospitals: Largest end-user segment with 45.0% share and USD 599 million in 2025 due to centralized access to endoscopy, pathology, imaging, and oncology services. Diagnostic Laboratories: Held 25.0% share with USD 333 million in 2025, supported by outsourcing of advanced pathology and molecular testing services. Oncology Clinics: Accounted for 15.0% share with USD 200 million in 2025, driven by biomarker-guided treatment planning. Cancer Centers: Represented 10.0% share with USD 133 million in 2025 due to multidisciplinary gastric cancer management models. Research Institutions: Held 5.0% share with USD 67 million in 2025 through translational oncology and biomarker research activities. By Geography North America: Largest regional segment with 35.0% share and USD 466 million in 2025, supported by advanced diagnostic infrastructure and precision oncology adoption. Europe: Accounted for 28.0% share with USD 372 million in 2025, supported by organized cancer programs and pathology modernization. Asia Pacific: Represented 25.0% share with USD 333 million in 2025, driven by high gastric cancer incidence and expanding diagnostic access. Latin America: Held 7.0% share with USD 93 million in 2025, supported by improving healthcare infrastructure and cancer diagnostic availability. Middle East & Africa: Accounted for 5.0% share with USD 67 million in 2025, with growth influenced by gradual expansion of oncology services and diagnostic capabilities. Recurring Reagents Lead While Molecular Platforms Drive the Highest Growth Recurring Consumables Anchor Product Revenue Leading Segment – By Product Type: Reagents & Consumables Reagents & Consumables represent the leading product segment in the Gastric Cancer Diagnostics Market, accounting for 50.0% share with USD 665 million in 2025 and projected to reach USD 1.05 billion by 2032, expanding at a CAGR of 6.7%. The segment leads because gastric cancer diagnosis requires continuous consumption of laboratory materials across multiple diagnostic stages, including biopsy sample preparation, tissue processing, staining, immunohistochemistry testing, and molecular biomarker evaluation. Unlike diagnostic instruments that involve periodic capital purchases, reagents and consumables generate recurring utilization across hospitals, pathology laboratories, and cancer centers. The increasing adoption of biomarker-based gastric cancer management has further strengthened this segment. Testing for HER2, PD-L1, MSI, and other molecular characteristics requires specialized reagents and assay kits, supporting continued use of pathology consumables. Companies such as Roche Diagnostics, Agilent Technologies, and Thermo Fisher Scientific maintain strong positions through pathology reagents, molecular assay solutions, and laboratory consumable portfolios used in gastric cancer testing workflows. Integrated Diagnostic Platforms Accelerate Product-Segment Growth Fastest-Growing Segment – By Product Type: Diagnostic Systems & Platforms Diagnostic Systems & Platforms represent the fastest-growing product segment, accounting for 25.0% share valued at USD 333 million in 2025 and projected to reach USD 570 million by 2032, expanding at a CAGR of 8.0%. Growth is driven by the transition toward integrated diagnostic workflows combining pathology automation, molecular testing, digital pathology, and artificial intelligence-assisted analysis. Healthcare providers are increasingly adopting connected diagnostic platforms that improve workflow efficiency, standardize interpretation, and support complex biomarker assessment. Digital pathology systems, automated staining platforms, and integrated molecular diagnostic solutions are gaining importance in tertiary hospitals and cancer centers where gastric cancer cases require comprehensive evaluation. Companies such as Leica Biosystems, Roche Diagnostics, and Thermo Fisher Scientific are advancing platforms that combine laboratory automation with precision oncology applications. Endoscopy Anchors Diagnosis as Molecular Testing Expands Leading Segment – By Diagnostic Technology: Endoscopy & Biopsy Endoscopy & Biopsy is the leading technology segment in the Gastric Cancer Diagnostics Market, accounting for 35.0% share with USD 466 million in 2025 and projected to reach USD 700 million by 2032, expanding at a CAGR of 6.1%. The segment maintains leadership because upper gastrointestinal endoscopy with biopsy remains the definitive diagnostic approach for confirming gastric cancer. Tissue acquisition is essential before pathological classification, biomarker testing, or treatment planning, making biopsy-based diagnosis central to the entire gastric cancer care pathway. The segment benefits from continued utilization of high-definition endoscopy systems, image-enhanced visualization technologies, and endoscopic ultrasound platforms. Companies such as Olympus and Fujifilm hold strong positions through gastrointestinal endoscopy portfolios used for lesion detection, biopsy guidance, and diagnostic evaluation. Biomarker-Based Treatment Selection Elevates Molecular Diagnostics Fastest-Growing Segment – By Diagnostic Technology: Molecular Diagnostics Molecular Diagnostics represent the fastest-growing technology segment, accounting for 20.0% share with USD 266 million in 2025 and projected to reach USD 550 million by 2032, expanding at a CAGR of 10.9%. The segment is expanding due to the increasing role of biomarker-based treatment selection in gastric cancer management. Molecular testing enables identification of clinically relevant characteristics such as HER2 amplification, PD-L1 expression, MSI status, and genomic alterations that influence therapy selection. The shift toward precision oncology is increasing utilization of PCR-based testing, next-generation sequencing, and companion diagnostic assays. Companies such as Illumina, Thermo Fisher Scientific, Roche Diagnostics, and Agilent Technologies support this segment through sequencing platforms, molecular assays, and biomarker testing solutions. Adenocarcinoma Drives Diagnostic Volume Across the Disease Landscape Leading Segment – By Disease Type: Gastric Adenocarcinoma Gastric Adenocarcinoma is the dominant disease segment, accounting for 88.0% share with USD 1.17 billion in 2025 and projected to reach USD 1.89 billion by 2032, expanding at a CAGR of 7.1%. The segment dominates because adenocarcinoma represents the majority of gastric cancer cases globally and requires comprehensive diagnostic evaluation, including biopsy confirmation, histopathological classification, staging imaging, and molecular profiling. The high clinical prevalence of gastric adenocarcinoma supports consistent utilization of diagnostic procedures across hospitals, oncology centers, and pathology laboratories. Advanced Classification Expands Testing for Rare Gastric Malignancies Fastest-Growing Segment – By Disease Type: Other Gastric Malignancies Other Gastric Malignancies represent the fastest-growing disease segment, accounting for 4.0% share with USD 53 million in 2025 and projected to reach USD 100 million by 2032, expanding at a CAGR of 9.5%. Although smaller in patient volume, this segment is growing due to improved pathological classification and recognition of rare gastric tumors requiring specialized diagnostic assessment. Advances in immunohistochemistry and molecular characterization are improving differentiation of uncommon gastric malignancies from conventional adenocarcinoma. Hospitals Centralize Multidisciplinary Diagnostic Workflows Leading Segment – By End User: Hospitals Hospitals represent the leading end-user segment, accounting for 45.0% share with USD 599 million in 2025 and projected to reach USD 970 million by 2032, expanding at a CAGR of 7.1%. Hospitals dominate because gastric cancer diagnosis requires coordinated access to gastroenterology, endoscopy, pathology, radiology, and oncology services. Large hospitals and academic medical centers typically maintain the infrastructure required for biopsy processing, staging imaging, molecular testing, and multidisciplinary treatment planning. Specialized Laboratories Expand Through Outsourced Molecular Testing Fastest-Growing Segment – By End User: Diagnostic Laboratories Diagnostic Laboratories represent the fastest-growing end-user segment, accounting for 25.0% share with USD 333 million in 2025 and projected to reach USD 560 million by 2032, expanding at a CAGR of 7.7%. Growth is supported by increasing outsourcing of specialized pathology and molecular testing services. Hospitals increasingly rely on centralized laboratories for advanced biomarker testing, genomic profiling, and complex diagnostic interpretation without maintaining all capabilities internally. Companies providing laboratory automation, molecular diagnostics, and pathology solutions benefit from this shift toward specialized diagnostic networks. North America Maintains Leadership Through Precision Diagnostic Infrastructure Leading Region – North America North America represents the leading regional segment, accounting for 35.0% share with USD 466 million in 2025 and projected to reach USD 760 million by 2032, expanding at a CAGR of 7.2%. The region leads due to advanced cancer diagnostic infrastructure, widespread endoscopy availability, strong pathology networks, and early adoption of molecular diagnostics. The United States contributes significantly through established oncology centers, reimbursement-supported diagnostic services, and high utilization of biomarker testing. High Disease Burden and Expanding Capacity Accelerate Asia Pacific Growth Fastest-Growing Region – Asia Pacific Asia Pacific represents the fastest-growing regional segment, accounting for 25.0% share with USD 333 million in 2025 and projected to reach USD 590 million by 2032, expanding at a CAGR of 8.5%. Growth is driven by the high gastric cancer burden in China, Japan, and South Korea, along with expansion of endoscopy infrastructure, cancer screening programs, and molecular diagnostic capabilities. Japan and South Korea have advanced gastric cancer screening ecosystems, while China is rapidly expanding oncology hospitals and diagnostic laboratory capacity. Companies such as Olympus and Fujifilm have strong regional relevance due to their gastrointestinal endoscopy portfolios, while global molecular diagnostic companies are expanding precision oncology testing capabilities across major Asian healthcare markets. Roche Diagnostics Anchors the Integrated Biomarker and Pathology Ecosystem Roche Diagnostics Roche Diagnostics is considered one of the leading companies in the Gastric Cancer Diagnostics Market due to its broad portfolio spanning tissue diagnostics, immunohistochemistry (IHC), companion diagnostics, digital pathology, and molecular testing solutions. The company plays a significant role in gastric cancer diagnosis by supporting biomarker-based patient classification, particularly through HER2 and PD-L1 testing workflows that influence targeted therapy and immunotherapy selection. Roche’s VENTANA automated staining platforms, pathology reagents, and companion diagnostic assays are widely integrated into hospital and reference laboratory workflows for standardized biomarker evaluation. The company’s competitive strength comes from its ability to connect diagnostic testing with precision oncology treatment decisions. In gastric cancer, accurate identification of biomarkers such as HER2 expression and PD-L1 status is increasingly important because treatment pathways depend on molecular characteristics rather than diagnosis alone. Roche’s integrated ecosystem combining tissue diagnostics, digital pathology, and molecular solutions positions it strongly among oncology diagnostic providers. The company continues to expand its role through automation, AI-supported pathology approaches, and technologies designed to improve laboratory efficiency and diagnostic consistency. Specialized Diagnostic Companies Strengthen Individual Testing Pathways Danaher Corporation (Leica Biosystems, Cepheid): A major pathology and molecular diagnostics provider with strong laboratory workflow solutions, but its gastric cancer positioning is more diversified across oncology rather than specifically centered on gastric cancer diagnostics. Thermo Fisher Scientific: A key molecular diagnostics and sequencing technology provider supporting genomic profiling and laboratory workflows, but it primarily contributes through broader precision medicine applications rather than being a dominant gastric cancer-specific diagnostic company. Olympus Corporation: A leading gastrointestinal endoscopy technology provider supporting gastric cancer detection and biopsy procedures, but its focus is concentrated on endoscopic equipment rather than the complete diagnostic ecosystem. Fujifilm Holdings Corporation: A significant player in gastrointestinal endoscopy and imaging technologies, particularly in Asian markets, but its gastric cancer diagnostic portfolio is narrower compared with integrated pathology and molecular diagnostic companies. Illumina: An important next-generation sequencing technology provider supporting genomic profiling, but its role remains concentrated in advanced molecular testing rather than routine gastric cancer diagnosis. Agilent Technologies: A recognized pathology and immunohistochemistry solutions provider, but its portfolio represents a supporting role within gastric cancer biomarker testing rather than overall market leadership. Precision Oncology, Liquid Biopsy, and AI Pathology Define the Next Commercial Frontier The future trajectory of the Gastric Cancer Diagnostics Market will be shaped by the transition from conventional disease confirmation toward comprehensive precision oncology ecosystems. While endoscopy, biopsy, and pathology will remain the clinical foundation, the largest commercial opportunities will emerge from technologies that improve molecular characterization, accelerate treatment selection, and enable more personalized therapeutic decisions. As gastric cancer management increasingly depends on biomarkers such as HER2, PD-L1, CLDN18.2, MSI, and emerging genomic signatures, diagnostic companies that can integrate tissue analysis, molecular testing, artificial intelligence, and clinical decision-support platforms are positioned to capture expanding value across the care pathway. Significant whitespace exists in early detection and minimally invasive diagnostic approaches. Current diagnosis often occurs after symptom development and relies heavily on invasive endoscopic biopsy procedures. Future opportunities are expected in liquid biopsy platforms, circulating tumor DNA (ctDNA) analysis, methylation-based biomarkers, and multi-omics testing approaches that can identify disease at earlier stages or support longitudinal monitoring. These technologies could expand the diagnostic market beyond initial confirmation toward recurrence surveillance, treatment response assessment, and population-level screening applications in high-incidence regions. Another major opportunity lies in developing integrated companion diagnostic platforms aligned with the expanding gastric cancer therapy pipeline. The emergence of targeted therapies and immunotherapies is increasing the need for accurate patient segmentation before treatment initiation. Diagnostic providers capable of offering validated assays linked with approved or emerging therapies, particularly for CLDN18.2-directed therapies, HER2-targeted agents, immune checkpoint inhibitors, and next-generation targeted treatments, are likely to gain strategic importance through partnerships with pharmaceutical companies. Regional expansion represents an additional growth avenue, particularly across Asia Pacific, where gastric cancer incidence remains high but diagnostic access varies significantly between countries. Investments in screening infrastructure, endoscopy capacity, pathology modernization, and centralized laboratory networks are expected to create opportunities for diagnostic companies to establish scalable solutions. Emerging healthcare markets may increasingly adopt automated pathology systems and outsourced molecular testing models rather than building fully independent laboratory capabilities. Artificial intelligence-enabled pathology and digital diagnostic workflows represent another high-value opportunity area. AI-based image analysis, automated biomarker scoring, and cloud-connected pathology platforms can address challenges related to diagnostic consistency, specialist shortages, and increasing testing complexity. Companies that successfully combine diagnostic accuracy with workflow efficiency will likely move beyond being equipment suppliers toward becoming essential partners in oncology decision-making. Overall, the Gastric Cancer Diagnostics Market is expected to evolve toward a connected, biomarker-driven, and data-enabled diagnostic environment. Future commercial leaders will likely be those capable of combining routine diagnostic infrastructure with advanced molecular intelligence, enabling earlier detection, improved patient stratification, and seamless integration between diagnosis and therapy selection. The market opportunity will increasingly shift from individual diagnostic tests toward integrated precision oncology platforms supporting the entire gastric cancer management continuum. Gastric Cancer Diagnostics Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.33 Billion Revenue Forecast in 2032 USD 2.17 Billion Overall Growth Rate CAGR of 7.35% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Product Type, By Diagnostic Technology, By Disease Type, By End User, By Geography By Product Type Reagents & Consumables, Diagnostic Instruments, Diagnostic Systems & Platforms By Diagnostic Technology Endoscopy & Biopsy, Molecular Diagnostics, Immunohistochemistry (IHC), Imaging-Based Diagnostics, Blood-Based Biomarker Testing By Disease Type Gastric Adenocarcinoma, Gastric Lymphoma, Other Gastric Malignancies By End User Hospitals, Diagnostic Laboratories, Oncology Clinics, Cancer Centers, Research Institutions By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Large global gastric cancer burden, recurring biopsy and pathology testing, expanding biomarker-guided treatment selection, growth of molecular and companion diagnostics, digital pathology adoption, and emerging liquid biopsy technologies Customization Option Available upon request Frequently Asked Question About This Report Q1. What role do diagnostic technologies play in improving gastric cancer management? A1. Diagnostic technologies enable early detection, pathological confirmation, staging, and biomarker identification required for personalized treatment decisions. Endoscopy with biopsy remains the foundation of diagnosis, while molecular testing, immunohistochemistry, and digital pathology increasingly guide targeted therapy and immunotherapy selection. Q2. Why does endoscopy and biopsy remain the leading diagnostic technology segment? A2. Endoscopy and biopsy accounted for approximately 35.0% share and USD 466 million in 2025 because tissue confirmation remains essential before classifying gastric tumors, determining disease characteristics, performing biomarker evaluation, and selecting appropriate treatment strategies. Q3. Why are molecular diagnostics considered the fastest-growing technology area? A3. Molecular diagnostics represented approximately 20.0% share and USD 266 million in 2025 and are projected to grow at a 10.9% CAGR due to increasing demand for biomarker-based treatment selection. Testing for HER2, PD-L1, MSI, CLDN18.2, and genomic alterations is becoming increasingly important as gastric cancer therapy moves toward precision oncology. Q4. Why do reagents and consumables represent the leading product segment? A4. Reagents and consumables accounted for approximately 50.0% share and USD 665 million in 2025 because gastric cancer diagnosis requires continuous use of pathology reagents, biopsy processing materials, immunohistochemistry kits, and molecular assay components across hospitals, laboratories, and cancer centers. Q5. How are biomarker testing approaches influencing future diagnostic development? A5. Biomarker testing is transforming diagnostic workflows by enabling patient selection for targeted and immune-based therapies. HER2 testing supports HER2-directed treatment, PD-L1 evaluation guides checkpoint inhibitor use, and CLDN18.2 testing helps identify patients eligible for emerging targeted therapies such as zolbetuximab. Q6. Why are diagnostic laboratories becoming an important growth segment? A6. Diagnostic laboratories are projected to be the fastest-growing end-user segment, expanding at approximately 7.7% CAGR, because hospitals increasingly outsource advanced pathology, molecular profiling, genomic testing, and specialized biomarker analysis to centralized laboratory networks. Q7. Which region is expected to experience the fastest growth in adoption? A7. Asia Pacific is the fastest-growing regional market, projected to expand at approximately 8.5% CAGR. Growth is supported by the high gastric cancer burden in countries such as China, Japan, and South Korea, along with expanding endoscopy infrastructure, cancer screening programs, and molecular diagnostic capabilities. Q8. What future technologies are expected to create new opportunities? A8. Future opportunities are expected from liquid biopsy, circulating tumor DNA analysis, multi-omics testing, AI-enabled digital pathology, and integrated companion diagnostic platforms. These technologies may improve early detection, treatment monitoring, recurrence surveillance, and personalized therapy selection across the gastric cancer care pathway. Sources: International Agency for Research on Cancer (IARC) – Global Cancer Observatory (GLOBOCAN) Supports global gastric cancer incidence, mortality burden, regional disease distribution, and cancer epidemiology data used for market assessment. Source: IARC Global Cancer Observatory https://gco.iarc.who.int/ World Health Organization (WHO) – Cancer Fact Sheets and Cancer Control Programs Supports global cancer burden, prevention strategies, screening approaches, and healthcare-system requirements for cancer diagnosis. Source: WHO Cancer https://www.who.int/health-topics/cancer National Cancer Institute (NCI) – Stomach Cancer Statistics and Treatment Information Supports U.S. gastric cancer incidence, mortality, survival statistics, diagnostic pathways, staging approaches, and biomarker-driven treatment strategies. Source: NCI Cancer Information https://www.cancer.gov/types/stomach American Cancer Society – Stomach Cancer Statistics and Diagnostic Approaches Supports U.S. gastric cancer patient burden, endoscopy-based diagnosis, biopsy confirmation, staging procedures, and treatment pathways. Source: American Cancer Society https://www.cancer.org/cancer/types/stomach-cancer.html National Comprehensive Cancer Network (NCCN) – Gastric Cancer Clinical Practice Guidelines Supports the role of endoscopy, biopsy, HER2 testing, PD-L1 evaluation, MSI testing, molecular profiling, and biomarker-guided gastric cancer treatment selection. Source: NCCN Guidelines https://www.nccn.org/guidelines European Society for Medical Oncology (ESMO) – Gastric Cancer Clinical Guidelines Supports multidisciplinary gastric cancer management, molecular classification, HER2 testing, PD-L1 assessment, MSI evaluation, and precision oncology approaches. Source: ESMO Clinical Practice Guidelines https://www.esmo.org/guidelines College of American Pathologists (CAP) – HER2 Testing Guidelines for Gastric and Gastroesophageal Junction Cancer Supports HER2 immunohistochemistry, ISH testing, pathology scoring standards, and companion diagnostic requirements for HER2-targeted treatment selection. Source: CAP Guidelines https://www.cap.org/protocols-and-guidelines Roche Diagnostics – VENTANA CLDN18 (43-14A) RxDx Assay Supports CLDN18.2 biomarker testing for identifying gastric cancer patients eligible for zolbetuximab (Vyloy) therapy. Source: Roche Diagnostics https://diagnostics.roche.com/ Roche Diagnostics – VENTANA HER2 Pathway and Companion Diagnostic Solutions Supports HER2 testing workflows, automated immunohistochemistry platforms, and biomarker assessment for HER2-positive gastric cancer treatment selection. Source: Roche Diagnostics https://diagnostics.roche.com/ Agilent Technologies – PD-L1 IHC 22C3 pharmDx and 28-8 pharmDx Assays Supports PD-L1 biomarker testing used for immune checkpoint inhibitor treatment selection in gastric and gastroesophageal cancers. Source: Agilent Pathology Solutions https://www.agilent.com/ U.S. Food and Drug Administration (FDA) – Companion Diagnostics Guidance and Approved Diagnostic Devices Supports regulatory requirements for companion diagnostics, biomarker-based oncology testing, and approval pathways for precision cancer diagnostics. Source: FDA Companion Diagnostics https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics FDA – Medical Device Databases and Endoscopy-Related Device Information Supports regulatory background for endoscopy systems, biopsy devices, pathology equipment, and diagnostic platforms. Source: FDA Medical Devices https://www.fda.gov/medical-devices Olympus Corporation – Gastrointestinal Endoscopy Systems Supports commercial role of upper gastrointestinal endoscopy systems, biopsy-guided diagnosis, image-enhanced endoscopy, and gastric cancer detection workflows. Source: Olympus Medical Systems https://medical.olympusamerica.com/ Fujifilm Healthcare – Gastrointestinal Endoscopy and Imaging Systems Supports advanced endoscopy technologies, image-enhanced visualization, and gastric lesion detection platforms. Source: Fujifilm Healthcare https://healthcaresolutions-us.fujifilm.com/ Thermo Fisher Scientific – Oncology Molecular Diagnostics and Sequencing Solutions Supports molecular profiling, next-generation sequencing, genomic testing, and biomarker analysis used in precision oncology workflows. Source: Thermo Fisher Scientific https://www.thermofisher.com/ Illumina – Next Generation Sequencing Platforms for Oncology Applications Supports genomic profiling technologies, tumor sequencing, and molecular characterization approaches relevant to gastric cancer precision medicine. Source: Illumina Oncology https://www.illumina.com/oncology.html Leica Biosystems – Digital Pathology and Automated Tissue Diagnostics Supports digital pathology, automated staining, image analysis, and pathology workflow modernization in oncology diagnostics. Source: Leica Biosystems https://www.leicabiosystems.com/ National Institutes of Health (NIH) – Precision Medicine Initiative Supports biomarker-driven medicine, molecular characterization, genomics, and personalized treatment strategies influencing cancer diagnostics. Source: NIH Precision Medicine https://commonfund.nih.gov/precisionmedicine Nature Reviews Cancer – Molecular Classification and Biomarker-Based Gastric Cancer Research Supports emerging gastric cancer molecular subtypes, biomarker discovery, immunotherapy selection, and targeted diagnostic strategies. Source: Nature Reviews Cancer https://www.nature.com/nrc/ The Cancer Genome Atlas (TCGA) – Gastric Cancer Molecular Classification Research Supports genomic characterization of gastric cancer, including molecular subtypes such as EBV-positive tumors, microsatellite instability, genomic stability, and chromosomal instability groups. Source: TCGA Program https://www.cancer.gov/ccg/research/genome-sequencing/tcga Table of Contents - Global Gastric Cancer Diagnostics Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Diagnostic Technology, Disease Type, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Diagnostic Technology, Disease Type, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Diagnostic Technology, Disease Type, and End User Investment Opportunities in the Gastric Cancer Diagnostics Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Molecular Diagnostics, Biomarker Testing, Companion Diagnostics, Digital Pathology, Liquid Biopsy, and AI-Enabled Diagnostic Workflows Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Gastric Cancer Diagnostics in Biomarker-Guided Testing and Precision Oncology Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Validation Factors Role of Endoscopy, Biopsy, Molecular Diagnostics, Immunohistochemistry, Imaging, and Blood-Based Biomarker Testing in Market Expansion Precision Oncology, Companion Diagnostics, Digital Pathology, Liquid Biopsy, and Artificial Intelligence Trends in Gastric Cancer Diagnosis Global Gastric Cancer Diagnostics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Reagents & Consumables Diagnostic Instruments Diagnostic Systems & Platforms Market Analysis by Diagnostic Technology: Endoscopy & Biopsy Molecular Diagnostics Immunohistochemistry (IHC) Imaging-Based Diagnostics Blood-Based Biomarker Testing Market Analysis by Disease Type: Gastric Adenocarcinoma Gastric Lymphoma Other Gastric Malignancies Market Analysis by End User: Hospitals Diagnostic Laboratories Oncology Clinics Cancer Centers Research Institutions Market Analysis by Region: North America Europe Asia Pacific Latin America Middle East & Africa Regional Market Analysis North America Gastric Cancer Diagnostics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Diagnostic Technology, Disease Type, and End User Country-Level Breakdown: United States Canada Mexico Europe Gastric Cancer Diagnostics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Diagnostic Technology, Disease Type, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Gastric Cancer Diagnostics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Diagnostic Technology, Disease Type, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia Pacific Latin America Gastric Cancer Diagnostics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Diagnostic Technology, Disease Type, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Gastric Cancer Diagnostics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Diagnostic Technology, Disease Type, and End User Country-Level Breakdown: GCC Countries Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Roche Diagnostics Danaher Corporation (Leica Biosystems, Cepheid) Thermo Fisher Scientific Olympus Corporation Fujifilm Holdings Corporation Illumina, Inc. Agilent Technologies, Inc. Hologic, Inc. Bio-Rad Laboratories, Inc. QIAGEN N.V. Exact Sciences Corporation Guardant Health, Inc. Sysmex Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Biomarker Testing Portfolio, Diagnostic Platform Integration, Pathology Automation, Molecular Testing Capabilities, Endoscopy Portfolio, and Regional Presence Supplier Qualification and Clinical Compliance Capability Analysis Precision Oncology and Companion Diagnostic Positioning Molecular Diagnostics, Immunohistochemistry, and Digital Pathology Competitiveness Liquid Biopsy, Artificial Intelligence, and Advanced Biomarker Testing Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Diagnostic Technology, Disease Type, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Biomarker Testing, Clinical Validation, and Diagnostic Procurement Risk Analysis Technology Adoption Trends Across Endoscopy & Biopsy, Molecular Diagnostics, Immunohistochemistry (IHC), Imaging-Based Diagnostics, and Blood-Based Biomarker Testing List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Diagnostic Technology, Disease Type, and End User (2025 vs. 2032) Global Gastric Cancer Diagnostics Ecosystem and Value Chain Analysis